Itolizumab not checked
Biocon Limited · EQ001 · Bmab600
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
6 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks. BSC: similar to Arm B”In the company’s words, NCT04475588 on ClinicalTrials.gov
- Tested for
- GVHD (2 trials), Acute-graft-versus-host Disease (2 trials), aGVHD (2 trials), Coronavirus, Graft Versus Host Disease, Acute GVHD, Acute Respiratory Distress Syndrome, Cytokine Release Syndrome and 5 more
- Main trialPhase 3
- “This is a randomized controlled trial to evaluate the efficacy and safety of itolizumab in subjects hospitalized with COVID-19.”In the company’s words, NCT04605926 on ClinicalTrials.gov
- Other names
- EQ001 · Bmab600
Other drugs for GVHD
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- AxatilimabIncyte · Syndax Pharmaceuticals · Phase 3
- DFL24498Dompé Farmaceutici S.p.A · Phase 3
- RovadicitinibChia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Remestemcel-LMesoblast, Inc. · Phase 3
- RhPRG4Lubris Bio Pty Ltd · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Withdrawn | Apr 2021 | A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19 | |
| Phase 3Terminated | 22 Apr 2025 | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) | |
| Phase 2Completed | 7 Jul 2020 | Efficacy and Safety of Itolizumab in COVID-19 Complications | |
| Phase 1/2Completed | 21 Nov 2022 | A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD | |
| Phase 1Completed | 12 Oct 2021 | A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma | |
| Phase 1Completed | 16 Nov 2023 | Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026